Previously submitted to: JMIR Formative Research (no longer under consideration since Apr 25, 2023)
Date Submitted: Feb 23, 2022
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
The testing and administration of the Moderna vaccine in patients with an allergic history
ABSTRACT
Background:
Patients with a history of allergic conditions, prior medication or vaccine reactions, and or anxiety may be hesitant to obtain a COVID-19 vaccine. Social media and news outlets heighten patients' concerns, leaving medical professionals struggling to provide patients with adequate reassurance regarding their personal risk factors for vaccination. We aimed to provide evidenced-based skin testing to reduce the risk of serious reactions, provide reassurance to patients and safely vaccinate those in our community.
Objective:
To establish a protocol for testing and administration of the Moderna COVID-19 vaccine in patients with an allergic history.
Methods:
Data was collected from patients who voluntarily made appointments at the allergy clinic. Skin prick and intradermal testing was completed to determine patients risk of anaphylactic reactions. Eligible patients were then vaccinated.
Results:
Of the 22 patients tested, 19 (86%) had negative skin prick and intradermal tests. Of these patients, all 22 patients were successfully vaccinated.
Conclusions:
Skin prick and intradermal testing performed in an allergy clinic not only can help predict the risk of individual anaphylaxis, but it can also help decrease individual anxieties. In addition, the education that comes along with such a process including conversations regarding true allergic reactions vs side effects is an extremely important part of the vaccination strategy. It is important that as providers we are willing to discuss patients’ fears and either refer them to an allergist to discuss their concerns or offer them a vaccine strategy (extra monitoring time in office etc.) to help reduce those fears. Clinical Trial: non applicable
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.